Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 100
- Registration Number
- NCT04782687
- Locations
- ๐บ๐ธ
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
๐บ๐ธNew York Oncology Hematology, P.C., Albany, New York, United States
๐บ๐ธRocky Mountain Cancer Centers, Denver, Colorado, United States
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 15
- Registration Number
- NCT04768881
- Locations
- ๐บ๐ธ
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธMinnesota Oncology Hematology, Minneapolis, Minnesota, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
- Conditions
- Interventions
- Drug: CarfilzomibDrug: DexamethasoneOther: Quality-of-Life AssessmentDrug: PomalidomideOther: Questionnaire AdministrationDrug: SelinexorProcedure: X-Ray ImagingProcedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 81
- Registration Number
- NCT04764942
- Locations
- ๐บ๐ธ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 52
- Registration Number
- NCT04756401
- Locations
- ๐บ๐ธ
Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธState University of New York Upstate Medical University, Syracuse, New York, United States
๐บ๐ธUNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT04640779
- Locations
- ๐บ๐ธ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- ๐บ๐ธ
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธUS Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States
๐บ๐ธUniversity of Texas Southwestern, Dallas, Texas, United States
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 14
- Registration Number
- NCT04595994
- Locations
- ๐ช๐ธ
Hospital Universitario La Paz, Madrid, Spain
๐ช๐ธHospital Clรญnico San Carlos, Madrid, Spain
๐ช๐ธHU Vall d'Hebron, Barcelona, Spain
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 330
- Registration Number
- NCT04562389
- Locations
- ๐บ๐ธ
UAB Division of Hematology/Oncology, Birmingham, Alabama, United States
๐บ๐ธUCLA - Satellite Site, Encino, California, United States
๐บ๐ธCity of Hope, Duarte, California, United States
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 112
- Registration Number
- NCT04562870
- Locations
- ๐บ๐ธ
The Oncology Institute of Hope and Innovation, Pasadena, California, United States
๐บ๐ธIllinois Cancer Specialist, Niles, Illinois, United States
๐บ๐ธTexas Oncology - Northeast Texas, Tyler, Texas, United States
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 441
- Registration Number
- NCT04534725
- Locations
- ๐ฆ๐บ
St Vincent's Hospital, Fitzroy, Victoria, Australia
๐ฆ๐บPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia
๐ฆ๐บRoyal Melbourne Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.